Differential approach to the treatment of lower urinary tract symptoms in benign prostatic hyperplasia


Cite item

Full Text

Abstract

The article considers the current approaches to the treatment of benign prostatic hyperplasia (BPH). The data for etiology, clinic and diagnosis of BPH are presented. The possibilities of alpha1-adrenergic blockers and 5alpha -reductase inhibitors administration in BPH are discussed. The article substantiates methods of combination therapy using alpha1-blocker treatment (short course) and 5alpha-reductase inhibitors, and alpha1-blockers in combination with anticholinergic drugs in patients with BPH with symptoms of overactive bladder. Much attention is given to the treatment of acute urinary retention.

References

  1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-79.
  2. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoreceptor antagonist: a randomized, controlled trial in a patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76(3):325-36.
  3. Evans HS, Moller H. Resent trends in prostate cancer incidence and mortality in Southeast England. Eur Urol 2003;43(4):337-41.
  4. Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996;18(5):993-1004.
  5. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED et al. Campbell's Urology, 8th ed. Philadelphia, PA: WB Saunders Co 2002:1297-336.
  6. Labreque J, Randolph R, Davis R. Benign prostatic hyperplasia: an overview for pharmacists. Am J Manag Care 1999;5:661-69.
  7. Kuritzky L. Benign prostatic hyperplasia. Compr Ther 1998;24:130-36.
  8. McNeal JG. The prostate gland: morphology and pathobiology. Monogr Urol 1983;4:3-33.
  9. Jepsen JV, Bruskewitz RC. Clinical manifestation and indications for treatment. In: Lepor H, ed. Prostatic Diseases. Philadelphia, PA: WB Saunders Co 2000:123-42.
  10. Isaacs J, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1987;2(Suppl.):33-50.
  11. Bosch JL, Hop WC, Kirkels WJ, et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46(3 Suppl. A):34-40.
  12. Denis L, McConnell J, Yoshida O. The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, editors. Fours International Consultation on Benign Prostatic Hyperplasia (BPH). Paris: SCI 1998:669-84.
  13. Lepor H. Pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Rev in Urol 2004;6(Suppl. 9):3-10.
  14. Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997;49:548-57.
  15. Bates TS, Reynard JM, Peters TJ, et al. Determination of prostate volume with transrectal ultrasound: a study of intraobserver and interobserver variation. J Urol 1996;155:1299-300.
  16. Marks LS, Linton HJ, Gasior CL, et al. BPSA is a potential serum marker for benign prostatic hyperplasia (BPH). J Urol 2001;165:266(Abstract).
  17. Barry MJ, Flower FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
  18. Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-been of men. Prostate 1993;23(1):1-7.
  19. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999;6(3):819-22.
  20. American Urological Association. AUA guideline on the management of benign prostatic hyperplasia. 2003. Available from URL: http://www.auanet.org/timssnet/products/guidelines/bph_ management.com.
  21. Пытель Ю.А., Винаров А.З. Этиология и патогенез гиперплазии предстательной железы. В кн. Доброкачественная гиперплазия предстательной железы / Под ред. Н.А. Лопаткина. М., 1997. С. 19-32.
  22. Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты a-адреноблокаторами. Монография. М., 1998.
  23. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev in Urol 2004;6(Suppl. 9):53-59.
  24. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001;58(4):508-16.
  25. Akduman B, Grawford ED. Terazosin, doxazosin and prazosin: current clinical experience.
  26. Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Farm Med 1993;2(9):929-35.
  27. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148(5):1467-74.
  28. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154(1):105-09.
  29. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of the double-blind, placebo-controlled studies. Urology 1996;48(3):406-15.
  30. Djavan B, Marberger M. A meta-analysis of the efficacy and tolerability of alpha 1-adrenoreceptor antagonist in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
  31. Buzelin JM, Delauche-Cavallier MC, Roth S, et al. Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997;79:898-906.
  32. Сивков А.В. Медикаментозная терапия доброкачественной гиперплазии предстательной железы. Доброкачественная гиперплазия предстательной железы / Под ред. Лопаткина Н.А. М., 1999. С. 91-116.
  33. Chapple C. Selective 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996;29:129-44.
  34. Пушкарь Д.Ю., Лоран О.Б., Раснер П.И. Терапия альфа-адреноблокаторами - метод выбора в лечении обструктивного мочеиспускания у мужчин и женщин // Фарматека 2002. №.10(61). С. 35-40.
  35. Choong S, Emberton M. Acute urinary retention. BJU International 2000;85:186-201.
  36. Marberger MJ, Andersen JТ, Nickel JС, et al. Prostate Volume and Serum Prostate-Specific Antigen as Predictors of Acute Urinary Retention. European Urology 2000;38:563-68.
  37. Manikandan R, Srirangam SJ, O'Reilly PH, et al. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. BJU Int 2004;93(1):84-88.
  38. McNeill SA. Does acute urinary retention respond to alpha-blockers alone? Eur Urol 2001;39(Suppl. 6):7-12.
  39. Choong S, Emberton M. Acute urinary retention. BJU International 2000;85:186-201.
  40. McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004;45(3):325-32.
  41. Перепанова Т.С., Камалов А.А., Синюхин В.Н. и др. Урология 2001. №2. С. 16-18.
  42. Kumar V, Marr C, Bhuvangiri A, et al. A prospective study of conservatively managed acute urinary retention: prostate size matters. BJU Int 2000;86(7):816-19.
  43. Пушкарь Д.Ю., Раснер П.И. Опыт консервативного лечения острой задержки мочи у больных доброкачественной гиперплазией предстательной железы одновременным назначением двух уроселективных альфа-адреноблокаторов - альфузозина и тамсулозина // Фарматека. 2006. № 15(130). С. 48-54.
  44. McConnell JD. Prostatic grows: new insights into hormonal regulation. Br J Urol 1995;76(Suppl. 1):5-10.
  45. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61(Suppl. 1):2-7.
  46. Walsh PC, Madden JD, Harrod M. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291:944-9.
  47. Schalken JA. The androgen cascade in ageing men: blessing or curse? Eur Urol 2003;(Suppl. 2):8-12.
  48. Coffey DS, Shimazaki J, Williams-Ashman HG. Polymerization of deoxyribonucleotides in relation to androgen induced prostatic grows. Arch Biochem Biophys 1968;124(1):184-98.
  49. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5(5):545-57.
  50. Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53(3):574-80.
  51. Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implication for finasteride therapy of prostate carcinoma. Prostate 2003;57(2):134-39.
  52. Bruchovsky N, Sadar MD, Akakura K, et al. Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 1996;59:397-404.
  53. Silver RI, Wiley EJ, Davis DL, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 1994;152:433-37.
  54. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgen in male volunteers. J Clin Endocrinol Metab 1990;70:1136-41.
  55. Rittmaster RS, Stoner E, Thompson DL, et al. Effects of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989;10:259-62.
  56. Gormley GJ, Stoner E, Bruskewitz RS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992;327:1185-91.
  57. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
  58. Hagerty JA, Ginsberg PC, Metro MJ, et al. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in clinical practice. J Urol 2004;171:356.
  59. Roehrborn CG. The clinical benefits of dutasteride treatment for LUTS and BPH. Rev in Urol 2004;6(Suppl. 9):22-30.
  60. Debruyne F, et al. Efficacy and Safety of Long-TermTreatment with the Dual 5a-Reductase Inhibitor Dutasteride inMenwith Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2004;46:488-95.
  61. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003;349:215-24.
  62. Marks LS. Treatment of men with minimally symptomatic benign prostatic hyperplasia-pro: the argument in favor. Urology 2003;62:781-83.
  63. Корниенко В.И. Эффективность медикаментозной терапии больных доброкачественной гиперплазией предстательной железы Автореф. дисс. канд. мед. наук. СПб., 1997.
  64. Djavan B, Barkin J. Novel therapeutic strategies for managing BPH progression. Eur Urol 2003;(Suppl. 2):20-26.
  65. McConnell JD, For the MTOPS Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003;349:2385-96.
  66. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461-66.
  67. Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50(Suppl.):57-73.
  68. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6(Suppl. 11):S580-90.
  69. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2002;55(5A Suppl.):51-7.
  70. Brading AF, Turner WH. The instable bladder: towards a common mechanism. Br J Urol 1994;73(1):3-8.
  71. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49(4):651-59.
  72. Rovner ES, Wein AJK. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002;41(1):6-14.
  73. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005;22(12):1013-28.
  74. Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs 2004;64(8):885-912.
  75. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169(6):2253-56.
  76. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2420&mid=1085056570&magid=180

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies